Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reiterated by Numis Securities Ltd in a research note issued to investors on Tuesday. They presently have a GBX 260 ($3.39) price target on the stock. Numis Securities Ltd’s price target would indicate a potential upside of 57.58% from the stock’s previous close.

A number of other research firms have also weighed in on HZD. Panmure Gordon reaffirmed a “buy” rating and set a GBX 270 ($3.52) target price on shares of Horizon Discovery Group PLC in a report on Wednesday, June 1st. Beaufort Securities reissued a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Friday, September 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Horizon Discovery Group PLC has a consensus rating of “Buy” and an average price target of GBX 217.25 ($2.84).

Analyst Recommendations for Horizon Discovery Group PLC (LON:HZD)

Horizon Discovery Group PLC (LON:HZD) opened at 153.40 on Tuesday. The company’s market cap is GBX 144.33 million. The company’s 50-day moving average is GBX 160.39 and its 200-day moving average is GBX 160.58. Horizon Discovery Group PLC has a 52 week low of GBX 125.00 and a 52 week high of GBX 188.06.

About Horizon Discovery Group PLC

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.